Successful use of rituximab in a patient with Churg-Strauss syndrome and refractory central nervous system involvement

Annals of the Rheumatic Diseases

Volumn 69, Issue 6, 2010, Pages 1254-1255

  Saech, Jasemine ^a   Owczarzyk, Kasia ^a   Rösgen, Sylvia ^a   Petereit, Hela ^a   Hallek, Michael ^a   Rubbert Roth, Andrea ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYELOPEROXIDASE; RITUXIMAB; STEROID;

ADULT; ALLERGIC ASTHMA; CASE REPORT; CENTRAL NERVOUS SYSTEM; CHURG STRAUSS SYNDROME; DIZZINESS; DRUG PULSE THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EOSINOPHILIA; FOLLOW UP; HEMIPARESIS; HUMAN; LABORATORY TEST; LETTER; MALE; MONONEUROPATHY MULTIPLEX; NAUSEA AND VOMITING; NERVE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARALYSIS; PARESTHESIA; PRIORITY JOURNAL; PURPURA; SINUSITIS;

ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM DISEASES; CHURG-STRAUSS SYNDROME; HUMANS; IMMUNOLOGIC FACTORS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 77953688485     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.109850     Document Type: Letter

References (10)

1. Guillevin L, Pagnoux C, Mouthon L. Churg-Strauss syndrome. Semin Respir Crit Care Med 2004;25:535-45.
2. Guillevin L, Cohen P, Gayraud M, et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999;78:26-37.
3. Jayne D, Rasmussen N, Andrassy K, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003;349:36-44. (Pubitemid 36765101)
4. Stassen PM, Tervaert JWC, Stegeman CA. Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide. Ann Rheum Dis 2007;66:798-802.
5. Keogh KA, Wylam ME, Stone JH, et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005;52:262-8.
6. Pepper RJ, Fabre MA, Pavesio C, et al. Rituximab is effective in the treatment of refractory Churg-Strauss syndrome and is associated with diminished T-cell interleukin-5 production. Rheumatology (Oxford) 2008;47:1104-5.
7. Koukoulaki M, Smith KG, Jayne DR. Rituximab in Churg-Strauss syndrome. Ann Rheum Dis 2006;65:557-9.
8. Groot K, Harper L, Jayne DR. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009;150:670-80.
9. Honorati MC, Bovara M, Cattini L, et al. Contribution of interleukin 17 to human cartilage degradation and synovial inflammation in osteoarthritis. Osteoarthr Cartil 2002;10:799-807.
10. LeGrand A, Fermor B, Fink C, et al. Interleukin-1, tumor necrosis factor alpha, and interleukin-17 synergistically up-regulate nitric oxide and prostaglandin E2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum 2001;44:2078-83.